Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (5729)	12/4/1998 2:00:00 AM
From: Joe E.	Read Replies (2) of 6136

As the Everen update indicates, the December 1 treatment guidelines suggest using a protease inhibitor, generally counseling against a Sustiva based protease sparing regime. The guidelines are in a long pdf document, but there is a clear summary on page 2 or page ii. hivatis.org Generally the Sustiva fears seem to have been overblown, which may account for some of the strength in the stock. The guidelines also now recommend active treatment for those seroconverted (infected) within the last 6 months, which I think is new. This is an additional group being recommended for treatment. In the last version of the guidelines it could be inferred that such persons without symptoms did not need to be treated, although this was left ambiguous.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next